- Hovione Loures
- Allergic rhinitis
Hovione can customize Fluticasone propionate for inhalation with an unrivalled range of particle size reduction technologies for the production of tailor made API, featuring a near-perfect particle size distribution reproducibility with a low span and amorphous content, providing highly stable API.
Hovione Fluticasone Propionate is available since 2001 and is approved in branded, generic and 505b2 applications.
With a proven track record in developing and manufacturing high performance APIs Hovione offers a full range of API for inhalation, e.g. Salmeterol Xinafoate.
This is not to be construed as a representation of non-infringement or as an offer to sell in those countries where such would constitute an infringement of third parties’ patent rights.